These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis. Awatade NT; Uliyakina I; Farinha CM; Clarke LA; Mendes K; Solé A; Pastor J; Ramos MM; Amaral MD EBioMedicine; 2015; 2(2):147-53. PubMed ID: 26137539 [TBL] [Abstract][Full Text] [Related]
7. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors. Amico G; Brandas C; Moran O; Baroni D Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989 [TBL] [Abstract][Full Text] [Related]
8. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel. Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400 [TBL] [Abstract][Full Text] [Related]
9. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis. Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948 [TBL] [Abstract][Full Text] [Related]
10. Effect of apical chloride concentration on the measurement of responses to CFTR modulation in airway epithelia cultured from nasal brushings. Bratcher PE; Yadav S; Shaughnessy CA; Thornell IM; Zeitlin PL Physiol Rep; 2020 Oct; 8(19):e14603. PubMed ID: 33038073 [TBL] [Abstract][Full Text] [Related]
11. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction. Brewington JJ; McPhail GL; Clancy JP Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802 [TBL] [Abstract][Full Text] [Related]
12. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist. Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995 [TBL] [Abstract][Full Text] [Related]
13. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Van Goor F; Hadida S; Grootenhuis PD; Burton B; Stack JH; Straley KS; Decker CJ; Miller M; McCartney J; Olson ER; Wine JJ; Frizzell RA; Ashlock M; Negulescu PA Proc Natl Acad Sci U S A; 2011 Nov; 108(46):18843-8. PubMed ID: 21976485 [TBL] [Abstract][Full Text] [Related]
14. Emerging preclinical modulators developed for F508del-CFTR have the potential to be effective for ORKAMBI resistant processing mutants. Laselva O; Bartlett C; Popa A; Ouyang H; Gunawardena TNA; Gonska T; Moraes TJ; Bear CE J Cyst Fibros; 2021 Jan; 20(1):106-119. PubMed ID: 32741662 [TBL] [Abstract][Full Text] [Related]
15. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Clancy JP; Rowe SM; Accurso FJ; Aitken ML; Amin RS; Ashlock MA; Ballmann M; Boyle MP; Bronsveld I; Campbell PW; De Boeck K; Donaldson SH; Dorkin HL; Dunitz JM; Durie PR; Jain M; Leonard A; McCoy KS; Moss RB; Pilewski JM; Rosenbluth DB; Rubenstein RC; Schechter MS; Botfield M; Ordoñez CL; Spencer-Green GT; Vernillet L; Wisseh S; Yen K; Konstan MW Thorax; 2012 Jan; 67(1):12-8. PubMed ID: 21825083 [TBL] [Abstract][Full Text] [Related]
16. The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis. Guerra L; Favia M; Di Gioia S; Laselva O; Bisogno A; Casavola V; Colombo C; Conese M Expert Opin Drug Discov; 2020 Aug; 15(8):873-891. PubMed ID: 32290721 [TBL] [Abstract][Full Text] [Related]
17. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review. Yang H; Ma T Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311 [TBL] [Abstract][Full Text] [Related]
18. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM; N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693 [TBL] [Abstract][Full Text] [Related]
19. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL; N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692 [TBL] [Abstract][Full Text] [Related]
20. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination. Veit G; Roldan A; Hancock MA; Da Fonte DF; Xu H; Hussein M; Frenkiel S; Matouk E; Velkov T; Lukacs GL JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32853178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]